128 related articles for article (PubMed ID: 7520682)
1. Determination of serum levels of different cytokeratins in patients with uterine malignancies.
Ferdeghini M; Gadducci A; Prontera C; Castellani C; Annicchiarico C; Gagetti O; Facchini V; Bianchi R
Anticancer Res; 1994; 14(3B):1393-7. PubMed ID: 7520682
[TBL] [Abstract][Full Text] [Related]
2. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
6. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions.
Farzaneh F; Shahghassempour S; Noshine B; Arab M; Yaseri M; Rafizadeh M; Alizadeh K
Asian Pac J Cancer Prev; 2014; 15(9):3911-4. PubMed ID: 24935573
[TBL] [Abstract][Full Text] [Related]
7. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
Tsai SC; Kao CH; Wang SJ
Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
[TBL] [Abstract][Full Text] [Related]
8. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of cytokeratin 19 fragments in cervical cancer.
Nasu K; Etoh Y; Yoshimatsu J; Matsu T; Narahara H; Miyakawa I
Gynecol Obstet Invest; 1996; 42(4):267-70. PubMed ID: 8979101
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
13. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients.
Tempfer C; Hefler L; Haeusler G; Reinthaller A; Koelbl H; Zeisler H; Kainz C
Int J Cancer; 1998 Jun; 79(3):241-4. PubMed ID: 9645344
[TBL] [Abstract][Full Text] [Related]
14. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
[TBL] [Abstract][Full Text] [Related]
17. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
18. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]